Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Cantor Fitzgerald Reiterates Overweight Rating, $215 Price Target on Johnson & Johnson (JNJ) Post Earnings
-
Form 424B3 Cantor Fitzgerald Income
-
UPDATE: Cantor Fitzgerald Assumes Arcturus Therapeutics (ARCT) at Overweight
-
Form EFFECT Cantor Fitzgerald Income
-
EYP-1901 Peak Sales Opportunity is Underappreciated - Cantor Fitzgerald Reiterates EyePoint (EYPT) at Overweight
-
Cantor Fitzgerald Launches Cantor Fitzgerald Sustainable Infrastructure Fund
-
Cantor Fitzgerald Assumes Alaunos Therapeutics Inc. (TCRT) at Overweight
-
Sanara MedTech (SMTI) PT Raised to $50 at Cantor Fitzgerald Post Accretive Scendia Acquisition, Encourage Investors to Acquire Undervalued Shares
-
IDB BANK APPOINTS KENNETH SAVIO AS NEW CEO OF IDB CAPITAL
-
Cantor Fitzgerald Downgrades ContraFect (CFRX) to Neutral, Lowers PT to $1 from $15
-
Orchid Island Capital Announces Estimated Second Quarter 2022 Results, July 2022 Monthly Dividend and June 30, 2022 RMBS Portfolio Characteristics
-
Form POS AM Cantor Fitzgerald Income
-
Cantor Fitzgerald Reiterates Overweight Rating, $7 Price Target on VolitionRX (VNRX) Following Latest Nu.Q Data
-
Cantor Fitzgerald Reiterates Neutral Rating, $1 Price Target on TherapeuticsMD (TXMD) on Failed Acquisition
-
UPDATE: Cantor Fitzgerald Downgrades Humanigen (HGEN) to Neutral
-
UPDATE: Cantor Fitzgerald Starts BioMarin Pharmaceutical Inc. (BMRN) at Overweight
-
UPDATE: Cantor Fitzgerald Starts Alnylam Pharmaceuticals (ALNY) at Neutral
-
Latest Hutchinson (HCM) Data "Underscores Belief HCM's Pipeline is Underappreciated" - Cantor Fitzgerald Reiterates Overweight and $50 Price Target
-
Form 424B3 CANTOR FITZGERALD SUSTAI
-
Cantor Fitzgerald Starts Kura Oncology (KURA) at Overweight (CORRECTION)
-
We Encourage Investors to Acquire Nyxoah SA (NYXH) Shares - Cantor Fitzgerald Bullish on Stock Following FDA Approval of ACCESS Trial
-
UPDATE: Cantor Fitzgerald Starts Blucora Inc. (BCOR) at Overweight
-
Form 8-K Cantor Fitzgerald Income For: Jul 05
-
Investors fear earnings season will spark new equities selloff
-
"We Believe ARQ-151 Will Be Cleared For Take Off" - Cantor Fitzgerald Bullish on Arcutis Biotherapeutics (ARQT) Ahead of PDUFA
-
Canopy Growth (WEED:CN) (CGC) PT Lowered to Cdn$3.75 at Cantor Fitzgerald
-
89bio Announces Closing of its Upsized $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
-
Celldex Therapeutics (CLDX) Thoughts on EAACI and Phase 1b Barzolvolimab CSU Data - Cantor Fitzgerald
-
Form EFFECT CANTOR FITZGERALD SUSTAI
-
Form N-2/A CANTOR FITZGERALD SUSTAI
-
89bio Inc. (ETNB) Prices Upsized $94.5 Share and Warrant Offering at $3.55/sh
-
89bio, Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
-
Enigma Securities Receives FINRA Approval for Corporate Equity Securities Broker Services
-
Form 40-APP CANTOR FITZGERALD SUSTAI
-
Borqs’ Solar Energy Storage Systems Subsidiary Presents at Cantor Fitzgerald Conference Started in Hawaii with over $128 million in contracts to be signed within 2022, and now coming to California
-
HCW Announces Hiring of Senior Analyst, Mike Colonnese
-
Tilray (TLRY) PT Lowered to $5.75 at Cantor Fitzgerald
-
UPDATE: Cantor Fitzgerald Upgrades Aurora Cannabis (ACB:CN) (ACB) to Overweight, 'Attractively Valued Pure Cannabis Global Play'
-
AMPRIUS TECHNOLOGIES TO PRESENT AT CANTOR FITZGERALD TECHNOLOGY ESG CONFERENCE ON JUNE 29TH
-
Greater Competition Does Not Impact Investment Thesis - Cantor Fitzgerald Reiterates Amarin Corporation (AMRN)at Overweight
-
CARTESIAN GROWTH CORPORATION II ANNOUNCES THE SEPARATE TRADING OF ITS CLASS A ORDINARY SHARES AND WARRANTS, COMMENCING JUNE 27, 2022
-
CARTESIAN GROWTH CORPORATION II ANNOUNCES THE SEPARATE TRADING OF ITS CLASS A ORDINARY SHARES AND WARRANTS, COMMENCING JUNE 27, 2022
-
Enigma Securities Advances Digital Asset FinTech with Release of 'Front-to-Back Crypto Hub' for Institutions
-
/C O R R E C T I O N -- Enigma Securities/
-
Charge Enterprises to Present at the Cantor Fitzgerald Technology ESG Conference
-
Cantor Fitzgerald Reiterates Overweight Rating, $21 Price Target on SeaSpine Holdings (SPNE)
-
Sun Capital Partners and Sterling Partners Merge West Dermatology and Platinum Dermatology Partners
-
Form 424B3 Cantor Fitzgerald Income
-
Gorilla Investor Webcast Update
-
Gorilla Investor Webcast Update

